Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654
This examiner grants 57% of resolved cases
Mercy Hellen Sabila is an examiner in Tech Center 1600 and Art Unit 1654. The examiner has 270 resolved cases. The allowance rate for these matters is 57.0%. This metric provides a baseline for the likelihood of securing a patent grant during prosecution. The 57.0% rate is a primary data point for evaluating the probability of success in this specific Art Unit.
The interview lift is 46.4%. This value measures the increase in the probability of allowance following an interview. A lift of 46.4% indicates that engaging in a direct dialogue with the examiner can be a productive strategy. Practitioners should weigh this 46.4% figure when deciding whether to request a formal interview for their 270 resolved cases.
The median days to allowance is 1023. This figure represents the typical time span from filing to the issuance of a patent. A median of 1023 days informs the scheduling and budget expectations for applicants. This 1023 days duration is a factor in the overall prosecution timeline.
In Tech Center 1600, the examiner's 57.0% allowance rate and 270 resolved cases define the current landscape. The interview lift serves as a tool for navigating the prosecution process toward a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17049237 | USE OF A HYALURONIC ACID-BASED HYDROGEL FOR TREATMENT OF VOLUMETRIC MUSCLE LOSS INJURY | Non-Final OA | The Regents of The University of California |
| 17416584 | NUTRITIONAL COMPOSITION FOR INDUCING A FEELING OF SATIETY, A BETTER SLEEP AND/OR LIMITING NOCTURNAL AWAKING IN INFANTS OR YOUNG CHILDREN | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 19358715 | GLP-1R ANTAGONISM TO IMPROVE NUTRITION FOLLOWING GASTROINTESTINAL SURGERY | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19353711 | BUFFERED FORMULATIONS OF EXENDIN (9-39) | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17430664 | CO-FORMULATIONS OF AMYLIN ANALOGUES WITH INSULIN ANALOGUES FOR TREATMENT OF DIABETES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17348694 | DIMERIC COLLAGEN HYBRIDIZING PEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | University of Utah Research Foundation |
| 17773733 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | Final Rejection | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 17762191 | INTEGRIN RECEPTOR ALPHA V BETA 3 AND ITS LIGAND INVOLVED IN CHRONIC ITCH | Final Rejection | North Carolina State University |
| 18038633 | SYNTHETIC DNA BINDING DOMAINS AND USES THEREOF | Non-Final OA | The University of Chicago |
| 18567426 | Preparation | Final Rejection | Kewpie Corporation |
| 17416880 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | Non-Final OA | HANMI PHARM, CO., LTD. |
| 16650696 | METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18273962 | COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOF | Non-Final OA | BRIM Biotechnology, Inc. |
| 18021660 | TISSUE-DERIVED MATRIKINE COMPOSITIONS AND METHODS THEREFOR | Final Rejection | XYLYX BIO, INC. |
| 18038196 | RAS MUTANT EPITOPE PEPTIDE AND T CELL RECEPTOR RECOGNIZING RAS MUTANT | Non-Final OA | SHANGHAI GENBASE BIOTECHNOLOGY CO., LTD. |
| 18181621 | NOVEL PROINSULIN GLARGINE AND METHOD FOR PREPARING INSULIN GLARGINE THEREFROM | Non-Final OA | Amphastar Nanjing Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy